PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.43%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
-14.45%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
43.33%
Net income growth under 50% of AVXL's 91.89%. Michael Burry would suspect the firm is falling well behind a key competitor.
43.35%
EPS growth under 50% of AVXL's 91.88%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
43.35%
Diluted EPS growth under 50% of AVXL's 91.88%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.17%
Negative OCF growth while AVXL is at 24.41%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-15.15%
Negative FCF growth while AVXL is at 24.46%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-167027.54%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-35848.35%
Negative 5Y OCF/share CAGR while AVXL is at 63.84%. Joel Greenblatt would question the firm’s operational model or cost structure.
-39776.52%
Negative 3Y OCF/share CAGR while AVXL stands at 67.01%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-711192.96%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-12332.31%
Negative 5Y net income/share CAGR while AVXL is 28.63%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-13057.95%
Negative 3Y CAGR while AVXL is 81.26%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
90012.37%
Equity/share CAGR of 90012.37% while AVXL is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
5373.91%
5Y equity/share CAGR above 1.5x AVXL's 104.29%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
7310.97%
3Y equity/share CAGR above 1.5x AVXL's 109.87%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
955.36%
BV/share growth above 1.5x AVXL's 145.62%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-33.08%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
0.44%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
34.62%
SG&A growth well above AVXL's 53.07%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.